Protocols

Based on the available clinical literature, thymosin alpha-1 (TA-1) has been studied using various dosing protocols depending on the clinical indication:

Hepatitis B Treatment

Limited evidence suggests TA-1 has been used in combination with entecavir for HBV-related compensated cirrhosis, though specific dosing details from the available studies are not provided in the current evidence base.

Hepatitis C Treatment

Studies have investigated TA-1 in combination with interferon alpha and ribavirin for chronic hepatitis C patients, particularly those who are non-responders or relapsers to standard interferon-based therapy. However, the specific dosing protocols are not detailed in the available abstracts.

Other Indications

Clinical trials have examined TA-1 for:

Sepsis (Phase 3 completed trial)
Non-small cell lung cancer as maintenance therapy (Phase 2)
COVID-19 prevention in dialysis patients (Phase 2 completed)
Advanced colorectal cancer in combination with triple regimen therapy (Phase 2, currently recruiting)

Dosing Information Limitations

The current evidence base lacks specific details regarding:

Standard dosing ranges
Administration frequency
Duration of treatment
Route of administration
Dose modifications for different patient populations

Most studies appear to use TA-1 as combination therapy rather than monotherapy, but precise protocol details are not available in the provided abstracts.

Important Disclaimer: This information is for educational purposes only and represents a summary of research protocols found in the literature. This is not personalized medical advice. Dosing, administration, and treatment decisions should always be made by qualified healthcare professionals based on individual patient assessment and current clinical guidelines.

Thymosin Alpha-1 (TA-1)

Member access required